VivoSeq
Ophthalmology

Viral Conjunctivitis

10

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Viral Conjunctivitis is an early-stage landscape with 10 programs across 4 companies. The most active players are IVIEW Therapeutics Inc., NovaBay Pharmaceuticals, Inc., Javelin Pharmaceuticals. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

60/100

Attrition Rate

36/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

IVIEW Therapeutics Inc.

1 program

Phase 2N

NovaBay Pharmaceuticals, Inc.

1 program

Phase 2J

Javelin Pharmaceuticals

1 program

Phase 2Takeda logo

Takeda

3 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

11

clinical trials

Completed6 · 55%
Terminated4 · 36%
Unknown status1 · 9%

Clinical Trials

Trial Activity

11 trials

FST-100 in the Treatment of Acute Viral Conjunctivitis
Completed·Takeda logoTakeda·Phase 2·NCT01461954·132 enrolled
FST-100 in the Treatment of Acute Adenoviral Conjunctivitis
Completed·Takeda logoTakeda·Phase 2·NCT01470664·176 enrolled
Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis
Completed·IIVIEW Therapeutics Inc.·Phase 2·NCT03749317·135 enrolled
Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis
Completed·FFundação Altino Ventura·Phase 2/3·NCT01799863·50 enrolled
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis
Completed·NNovaBay Pharmaceuticals, Inc.·Phase 2·NCT01532336·500 enrolled
A Trial of Topical Dexamethasone Versus Artificial Tears for Treatment of Viral Conjunctivitis
Completed·UUniversity of Campinas, Brazil·Phase 3·NCT01481519·100 enrolled
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
Terminated·Takeda logoTakeda·Phase 3·NCT02998541·219 enrolled
An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis
Terminated·AAlcon Research·Phase 2·NCT00901693·452 enrolled
FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis
Terminated·Takeda logoTakeda·Phase 2·NCT00941486·30 enrolled
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
Terminated·Takeda logoTakeda·Phase 3·NCT02998554·156 enrolled
OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis
Unknown status·OOkogen·Phase 2·NCT03856645·219 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)